Sugi Predict

Sugi Predict / Targets / PGRMC2

PGRMC2

Membrane-associated progesterone receptor component 2 · O15173 · PGRMC2 on Sugi Atlas →

0 patent compounds predicted against PGRMC2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PGRMC2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills PHASE4COMPLETED
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification PHASE2/PHASE3RECRUITING
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer PHASE3COMPLETED
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy PHASE2ACTIVE_NOT_RECRUITING
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer PHASE2COMPLETED
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy PHASE2ACTIVE_NOT_RECRUITING
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer PHASE2COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer PHASE2WITHDRAWN
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients PHASE1COMPLETED
PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women nanRECRUITING
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status nanCOMPLETED
FES-PET for Patients Treated on NCI Protocol 8762 nanWITHDRAWN
Uterine Cavity Assessment and Endometrial Hormonal Receptors in Women With Peri and Post Menopausal Bleeding nanCOMPLETED
Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients nanUNKNOWN
Expression of Steroid Receptors in Endometrium nanCOMPLETED
A Randomized Controlled Study on the Effect of MRJPs on Improving Ovarian Function and Endometrial Receptivity nanRECRUITING
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus nanCOMPLETED
ERA Test in Patients With Recurrent Implantation Failure nanUNKNOWN
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy nanRECRUITING
The Effect of Progesterone on Human Endometrium nanCOMPLETED
21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis nanRECRUITING
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741 nanCOMPLETED
Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer nanUNKNOWN
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer nanCOMPLETED
Impact of Serum Progesterone in Modified Natural Cycles and Stimulated Cycles on Ongoing Pregnancy Rate nanCOMPLETED
Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PGRMC2 binder may also engage these)

ProteinNameSimilarity
Q5XIU9 — 0.996 Q5XIU9 →
Q80UU9 — 0.995 Q80UU9 →
P70580 — 0.980 P70580 →
Q5ZKN2 — 0.979 Q5ZKN2 →
Q5RED0 — 0.979 Q5RED0 →
PGRMC1 Membrane-associated progesterone receptor component 1 0.978 landscape →
Q17QC0 — 0.976 Q17QC0 →
Q95250 — 0.976 Q95250 →
O55022 — 0.975 O55022 →
Q6IUR5 — 0.972 Q6IUR5 →
Q9UMX5 — 0.967 Q9UMX5 →
Q1JQA5 — 0.965 Q1JQA5 →
Q5R6F1 — 0.965 Q5R6F1 →
P93422 — 0.963 P93422 →
Q9CQ45 — 0.962 Q9CQ45 →
Q8CG07 — 0.962 Q8CG07 →
Q9XHM1 — 0.961 Q9XHM1 →
O02810 — 0.961 O02810 →
Q2UM19 — 0.961 Q2UM19 →
Q96S55 — 0.960 Q96S55 →
Q9H078 — 0.960 Q9H078 →
METTL3 N6-adenosine-methyltransferase catalytic subunit 0.960 landscape →
Q9BYB0 — 0.960 Q9BYB0 →
Q9EQM6 — 0.960 Q9EQM6 →
O54935 — 0.960 O54935 →
Q62925 — 0.960 Q62925 →
Q0J6P7 — 0.959 Q0J6P7 →
Q8WVT3 — 0.959 Q8WVT3 →
Q9QXP6 — 0.959 Q9QXP6 →
Q80W04 — 0.959 Q80W04 →